Moderna stock closed Wednesday trading at $123.52 on October 19, 04:00
In comparison to Spikevax prototype booster mRNA-1273 after three months, Moderna (NASDAQ:MRNA) reported that its Omicron BA.1-targeting bivalent mRNA-1273.214 vaccine demonstrated greater antibody response as the fourth booster.
The company reported that a 50 g booster dose of mRNA-1273.214 elicited a superior neutralizing antibody response against Omicron BA.1 compared to a 50 g booster dose of mRNA-1273 in all participants regardless of prior infection 90 days after administration as a 4th booster shot in previously vaccinated and boosted participants.
According to a statement released by Moderna on Wednesday, superior effectiveness against Omicron BA.1 was also long-lasting, with greater antibody titers maintained for three months.
According to clinical trial data, the improved immune response brought on by our bivalent booster lasts for at least three months, according to Moderna CEO Stéphane Bancel. The business claims that the side effects of the bivalent shot were comparable to or less severe than those of a second or third dosage of the original vaccination.
Developments Promoting Moderna Stock Discussion
Later this year, Moderna anticipates the interim findings of their bivalent Omicron BA.4/BA.5 vaccine, mRNA-1273.222. Moderna stock fell 1.55% to $132.01 in premarket trading on October 19. The Omicron subvariants targeted by Moderna’s (NASDAQ:MRNA) Spikevax COVID vaccine, is recommended for use in populations of people 12 years of age and older who have already completed a primary vaccination course, according to the EMA on Wednesday.
Targets of the modified bivalent vaccination include the original coronavirus strain and the Omicron subvariants BA.4 and BA.5. After a modified Spikevax vaccination targeting Omicron BA.1 and the original strain was approved in September, the Committee for Medicinal Products for Human Use (CHMP) observed that this is the second adapted Spikevax vaccine that EMA has recommended for approval.
What You Should Understand About Moderna Stock
Featured Image- Megapixl @Ralfliebhold
Author Jowi Kwasu 
